Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Estrogens can improve skin aging but carry risks; more research is needed on safer treatments.

The patient's long-term hair loss was caused by leukemia treatments and low estrogen levels, worsened by her genetic tendency for hair loss.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

Glibenclamide slows breast cancer cell growth by stopping cell division.

Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.

Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.

The skin's ability to produce hormones is linked to various skin conditions, and better understanding this process could lead to new treatments.

Review finds no permanent solution for female hair loss.

Certain adrenal hormones can strongly stimulate oil gland growth in hamster skin, similar to male hormones.

Melasma is a skin condition linked to female hormones, genetics, UV exposure, and certain medications, but not to pituitary, adrenal, or thyroid diseases.

Male and female skin differ in many ways, which could lead to gender-specific skin treatments.

Reporter characteristics affect detection of hair loss from cancer therapy.

Testosterone therapy can help with androgen deficiency in women but should be used with caution and monitoring due to potential risks.

Testosterone therapy can help postmenopausal women with low sexual desire but needs more safety research and should be used with estrogen therapy.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

Enhancers and super-enhancers are key in controlling specific gene activity and can play a role in cancer development.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.

Hair loss in Androgenetic Alopecia is caused by genetics, aging, and lifestyle, leading to hair follicle shrinkage and related health risks.

Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Estrogen loss during menopause worsens skin health, but hormone replacement therapy may improve it, though more research is needed.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Androgen receptor inactivation delays skin cancer onset and reduces incidence in mice, with gender differences in susceptibility.

Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.

Some breast cancer chemotherapy can cause permanent hair loss.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.